Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease

NCT02792413 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT02792413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02792413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
Lead sponsor
University Hospital, Montpellier
Phase
Phase 4
Overall status
Terminated
Start date
November 19, 2018
Completion date
December 10, 2020
Enrollment
4 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

female with osteoporosis and chronic kidney disease